

Do you have patients with Recurrent Prostate Cancer?

HIFU may help.

Sonablate® 500: High Intensity Focused Ultrasound (HIFU)

A clinical trial is being conducted to determine the effectiveness and safety of the Sonablate® 500 device using focused ultrasound energy to treat patients who have localized recurrent prostate cancer following radiation therapy.

Eligible Participants must

- Have been treated with external beam radiation therapy two or more years prior.
- Have organ-confined recurrent prostate cancer T1 or T2.
- Be between the ages of 40 and 80.
- Have a Gleason score of less than or equal to 7.
- Have a PSA level between .5ng/mL and 10ng/mL.
- Have a recent (within 6 months) prostate biopsy that is positive for cancer cells.

There is **no cost** to enroll in this study and all potential participants must be screened before becoming a trial subject.

To find out more about this study
call **1-877-874-4389** or visit
www.ProstateCancerRecurrentTrial.org